REGENXBIO Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by REGENXBIO Inc. (RGNX) on June 4, 2021, regarding events occurring at the Company's 2021 Annual Meeting of Stockholders held on the same date. The filing details corporate governance actions, including the election of directors, ratification of auditors, executive compensation advisory votes, and amendments to the Company's Restated Certificate of Incorporation.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results rather than financial performance.
Material Changes and Voting Results
Stockholders approved several key proposals at the Annual Meeting:
- Proposal 1 (Director Elections): Three Class III directors were elected to serve until the 2024 annual meeting.
- Luke M. Beshar: 30,434,135 votes for.
- Kenneth T. Mills: 30,507,391 votes for.
- David C. Stump, M.D.: 22,955,386 votes for (notably higher withheld votes compared to other nominees).
- Proposal 2 (Auditor Ratification): Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2021, with 38,250,113 votes for.
- Proposal 3 (Executive Compensation): Stockholders approved, on an advisory basis, the compensation of named executive officers with 34,872,771 votes for.
- Proposal 4 (Federal Forum Selection): Stockholders approved an amendment to the Restated Certificate of Incorporation designating the federal district courts of the United States as the exclusive forum for claims arising under the Securities Act of 1933. This amendment was filed with the Delaware Secretary of State on June 4, 2021, with immediate effectiveness.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary on operations, or new risk factors. The primary legal change noted is the Federal Forum Selection Amendment, which limits the venue for securities law claims to federal courts unless the Company consents otherwise.
Key Facts for Investor Verification
- Verify the immediate effectiveness of the Federal Forum Selection Amendment filed on June 4, 2021.
- Review the voting results for David C. Stump, M.D., who received a significantly higher number of withheld votes compared to the other Class III director nominees.
- Confirm the term of the newly elected Class III directors extends through the 2024 annual meeting.
- Check the definitive proxy statement (Schedule 14A filed April 19, 2021) for detailed background on the proposals and executive compensation.